AAPL 248.58 0.8479% MSFT 453.21 0.9399% NVDA 137.4648 -1.3245% GOOGL 194.46 -0.4811% GOOG 195.97 -0.3762% AMZN 229.82 -0.1911% META 630.9 -0.2813% AVGO 179.8499 -1.8287% TSLA 420.25 -1.0641% TSM 192.5975 -0.715% LLY 781.77 -1.7914% V 314.5 0.2263% JPM 241.66 -0.7679% UNH 520.37 -2.4666% NVO 109.19 -2.2383% WMT 95.08 0.1264% LVMUY 135.51 -0.14% XOM 112.375 0.4065% LVMHF 682.0 0.3561% MA 533.22 -0.2301%
Last update at 2024-12-11T20:16:00Z
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
Tue 08 Oct 24, 05:05 PMAstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
Mon 07 Oct 24, 12:04 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 7582.26M | 6847.10M | 6391.02M | 4626.16M | 3953.56M |
Minority interest | -140.66000M | -82.93900M | 768.78M | 1056.44M | 477.34M |
Net income | 6091.39M | 5605.19M | 5159.65M | 3714.11M | 3210.01M |
Selling general administrative | 1172.84M | 1009.82M | 945.71M | 748.51M | 7121.07M |
Selling and marketing expenses | 10337.42M | 10443.42M | 9377.62M | 8712.08M | - |
Gross profit | 22256.41M | 21135.09M | 18685.32M | 15910.98M | 12218.99M |
Reconciled depreciation | 1047.94M | 865.47M | 808.81M | 691.60M | 655.25M |
Ebit | 7559.09M | 6817.40M | 6070.20M | 4658.59M | 3613.72M |
Ebitda | 8607.03M | 7682.87M | 6879.01M | 5350.18M | 3976.72M |
Depreciation and amortization | 1047.94M | 865.47M | 808.81M | 691.60M | - |
Non operating income net other | - | - | - | - | 0.00000M |
Operating income | 7559.09M | 6817.40M | 6070.20M | 4600.18M | 3976.72M |
Other operating expenses | 24177.27M | 21071.92M | 18885.54M | 17503.01M | 14483.45M |
Interest expense | 24.89M | 7.66M | 12.23M | 32.43M | 76.90M |
Tax provision | 1350.21M | 1158.97M | 1162.01M | 892.81M | 766.71M |
Interest income | - | - | - | - | - |
Net interest income | -24.89100M | -7.66400M | -12.23200M | -32.42600M | -76.90096M |
Extraordinary items | - | - | - | - | 0.00000M |
Non recurring | - | - | - | - | 0.00000M |
Other items | - | - | - | - | 0.00000M |
Income tax expense | 1350.21M | 1158.97M | 1162.01M | 892.81M | 766.71M |
Total revenue | 30936.90M | 27866.87M | 24942.20M | 22103.19M | 18468.73M |
Total operating expenses | 15496.78M | 14340.14M | 12628.65M | 11310.80M | 8233.71M |
Cost of revenue | 8680.49M | 6731.78M | 6256.88M | 6192.21M | 6249.74M |
Total other income expense net | 23.17M | 29.70M | 320.82M | 25.98M | -23.15082M |
Discontinued operations | - | - | - | - | 0.00000M |
Net income from continuing ops | 6232.05M | 5688.12M | 5229.01M | 3733.35M | 3186.85M |
Net income applicable to common shares | - | 5605.19M | 5159.65M | 3714.11M | 3080.80M |
Preferred stock and other adjustments | - | - | - | - | 0.00000M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 41769.77M | 34741.58M | 30070.21M | 26318.32M | 22694.43M |
Intangible assets | 1908.11M | 467.85M | 508.74M | 1135.66M | 805.39M |
Earning assets | - | - | - | - | - |
Other current assets | - | 177.75M | 36.57M | 562.22M | 1434.78M |
Total liab | 10127.90M | 7913.35M | 6969.13M | 6800.16M | 7672.00M |
Total stockholder equity | 30197.53M | 25986.67M | 22332.29M | 18461.72M | 15022.43M |
Deferred long term liab | 35.81M |